Posted inLatest News
SELLAS’ Cancer Vaccine Cuts AML Death Risk by 41% in Major Phase 3 Trial as FDA Filing Nears
SELLAS Life Sciences has announced promising results from a major late-stage clinical trial of its experimental cancer vaccine, galinpepimut-S (GPS), showing a 41% reduction in the risk of death among…
